mortality/aging
• mutants show accelerated mortality relative to Faslpr homozygotes, with a median survival of 16.4 weeks compared to 25.1 weeks for Faslpr homozygotes
|
immune system
• splenomegaly is increased more than in Faslpr homozygotes
|
• 3-fold increase in the number of CD4- CD8- double-negative T cells in the spleen compared to Faslpr homozygotes
|
• increase in number of CD4+ helper T cells compared to Faslpr homozygotes
|
• B cells have increased expression of activation markers CD44 and CD69 compared to Faslpr homozygotes, indicating increased B cell activation
|
• increase in concentration of every IgG isotype compared to Faslpr homozygotes, with most prominent increases in IgG2a and IgG3
|
• compared to Faslpr homozygotes
|
• compared to Faslpr homozygotes
|
• mice exhibit increased serum IFN-alpha concentration compared to Faslpr homozygotes
|
• lymphadenopathy is increased more than in Faslpr homozygotes
|
• splenic plasmacytoid dendritic cells (pDC) are more activated than those in single Faslpr homozygotes based on increased expression of MHC class II
• plasmacytoid DCs have an increased expression of the activation markers CD80 and CD86 compared to Faslpr homozygotes
|
• mutants exhibit an increase in the incidence and severity of autoimmune skin disease compared to single Faslpr homozygous littermates
• mutants develop exacerbated kidney disease (lupus nephritis) compared to single Faslpr homozygotes
|
• mutants show impaired ability to generate antibodies to DNA antigens compared to single Faslpr homozygotes, however they do generate antibodies reacting with cytoplasmic antigens that may include RNA
|
• mice exhibit an elevated baseline level of anti-Smith-ribonucleoprotein autoantibodies compared to single Faslpr homozygotes
|
• mutants develop exacerbated kidney disease (lupus nephritis) compared to Faslpr homozygotes
• a trend towards increased severity of interstitial infiltrates compared to Faslpr homozygotes
|
• increase in glomerular size, cellularity, and protein deposition in kidneys leading to glomerulonephritis
|
renal/urinary system
• mutants develop exacerbated kidney disease (lupus nephritis) compared to Faslpr homozygotes
• a trend towards increased severity of interstitial infiltrates compared to Faslpr homozygotes
|
• increase in glomerular size, cellularity, and protein deposition in kidneys leading to glomerulonephritis
|
• glomerular size and cellularity are increased compared to Faslpr homozygotes
|
hematopoietic system
• splenomegaly is increased more than in Faslpr homozygotes
|
• 3-fold increase in the number of CD4- CD8- double-negative T cells in the spleen compared to Faslpr homozygotes
|
• increase in number of CD4+ helper T cells compared to Faslpr homozygotes
|
• B cells have increased expression of activation markers CD44 and CD69 compared to Faslpr homozygotes, indicating increased B cell activation
|
• increase in concentration of every IgG isotype compared to Faslpr homozygotes, with most prominent increases in IgG2a and IgG3
|
• compared to Faslpr homozygotes
|
• compared to Faslpr homozygotes
|
homeostasis/metabolism
• mice exhibit increased serum IFN-alpha concentration compared to Faslpr homozygotes
|
growth/size/body
• splenomegaly is increased more than in Faslpr homozygotes
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
systemic lupus erythematosus | DOID:9074 |
OMIM:152700 OMIM:300809 OMIM:605480 OMIM:608437 OMIM:609903 OMIM:609939 OMIM:610065 OMIM:610066 OMIM:612254 OMIM:612378 OMIM:613145 OMIM:614420 |
J:113557 |